Almirall SA operates in the Pharmaceutical preparations sector.
In addition to historical fundamental analyses, the complete report available to purchase compares Almirall SA with three other
pharmaceutical manufacturers in Europe:
sales of 905.43 million Euros [US$1.08 billion]
of which 53%
was Product Sales, Net),
(712.30 million Euros [US$850.00 million]
of which 45%
was X-rays), and
Dermapharm Holding SE
based in GERMANY
(793.83 million Euros [US$947.29 million]
of which 59%
was Pharmaceuticals and other products).
During the first
quarter of 2021, sales at Almirall SA totalled
215.40 million Euro.
This is a drop of 10.7%
from the 241.31 million Euro in sales at the company during the first quarter in 2020.
Almirall SA reported sales of 807.43 million Euro (US$963.52 million)
December of 2020.
decrease of 5.6%
versus 2019, when the company's sales were 855.34 million Euro.
Contributing to the drop in overall sales was the 43.8% decline
in Dermatology, from 178.18 million Euro to 100.18 million Euro.
There were also decreases in sales in
Own Network (Spain) (down 1.0% to 534.41 million Euro)
However, these declines were partially offset by the increase in sales of
Licenses (up 32.1% to 146.64 million Euro)
Corporate (up 2.2% to 26.20 million Euro)